IonQ, Inc.
Quantum-compute-as-a-service (cloud QPU access) + on-prem system sales + government/enterprise R&D contracts; pre-profit, capital-markets-funded
The thesis on this name
State of Quantum Computing
The scale-and-M&A leg of the leader barbell. Most cash, biggest mcap (~$19B), highest 2026 revenue guide ($260-270M incl. acquired revenue), and the only player explicitly building the networking/interconnect layer (could monetize before fault-tolerant compute does). 'High potential' is real; 'undervalued' is a stretch at ~70x+ forward sales — classify it as a venture call option, not a value name.
State of Quantum Computing
Best-funded pure-play and likely sector consolidator (~$3.1B cash, Oxford Ionics + Capella) — a venture call option on trapped-ion + quantum networking, sized accordingly.
State of Quantum Computing
Largest, best-capitalized pure-play (~$3.1B cash post-raises, ~$19B mcap, 2026 rev guide $260-270M incl. acquired revenue). Vertically integrating via Oxford Ionics ($1.075B) + Capella (space QKD) + Lightsynq photonic interconnect. Sized as a venture call: you want exposure to the consolidator if trapped-ion/networking commercializes, but ~70x+ forward sales means most of the value is terminal/narrative. Starter only; accumulate on the inevitable 30-40% drawdowns.
Earnings, margins, COGS & capex
First public quantum firm past $100M annual GAAP revenue ($130.0M FY25, +202%), with Q1 FY26 accelerating to $64.7M (+755% YoY) on system sales + multi-year quantum contracts. Revenue is real but small relative to a ~$18.9B market cap; the company is structurally loss-making (FY25 net loss $510.4M; Q1 FY26 adj. EBITDA loss $96.8M) and funds itself from a ~$3.1B cash war chest raised via equity. The headline GAAP net-income prints (Q4'25 $753.7M, Q1'26 $805.4M) are non-cash warrant-revaluation gains, NOT operating earnings — adjusted EPS was -$0.34 in Q1 FY26.
Income statement — where each revenue dollar goes
% of revenueOf every $1 of revenue, ~99¢ is cost of goods and ~0¢ operating expense, leaving ~1¢ of operating profit (~510¢ net).
Revenue trend
Margins
loss widened with scale-up + M&A
widening; FY26 guided -$310M to -$330M
burn accelerating into the roadmap
missed -$0.25 consensus
COGS structure
Not separately headlined. COGS is system hardware (ion-trap chips, photonics/lasers, cryo/vacuum, control electronics) plus cloud-delivery and labor; high-touch, bespoke system builds keep unit costs elevated relative to revenue at current scale.
Capex
High and growing — manufacturing/data-center quantum systems, the imec/NKT Photonics photonics-integration program, Lightsynq (quantum memory/photonic interconnect), and the pending SkyWater foundry (which adds a capital-intensive semiconductor fab to the model). Vertical integration trades opex/capex now for supply-chain control later.
Latest earnings
Revenue beat: $64.7M vs ~$49.7M consensus (~30% above guide midpoint). Bottom line MISS on the metric that matters: adjusted EPS -$0.34 vs -$0.25 expected. GAAP net income of $805.4M / $2.19 EPS is a non-cash warrant-revaluation gain, not operating profit — the stock dipped on the print.
Raised FY26 revenue to $260–270M (from $225–245M) and Q2 FY26 to $65–68M; reaffirmed FY26 adj. EBITDA loss of -$310M to -$330M. ~100% organic growth signposted.
- Q1 FY26 revenue
- $64.7M (+755% YoY)
- Remaining performance obligations
- $470M (+554% YoY)
- Cash + investments
- ~$3.1B (Mar 31, 2026)
- Commercial / international / multi-product mix
- ~60% / ~35% / >33%
- Adj. EBITDA loss
- -$96.8M (-$85.0M ex-SkyWater)
Growth drivers
- Multi-year quantum contracts + system sales (RPO $470M, +554% YoY) giving multi-year revenue visibility
- Government/defense demand — DARPA QBI Stage B, SDA HALO ($39M tactical-space comms), MDA SHIELD IDIQ
- Newest systems (Tempo, Forte Enterprise) landing enterprise wins (AstraZeneca, NVIDIA, Toyota Tsusho, Ansys, Infineon) at ~20x demonstrated speedups
- Inorganic roadmap acceleration — Oxford Ionics electronic-qubit-control tech (closed) and Lightsynq interconnects toward networked, scaled systems
- Cloud distribution via AWS Braket, Azure Quantum, Google Cloud Marketplace lowering customer adoption friction
Reported financials — SEC EDGAR
Audited GAAP figures pulled from SEC filings · latest filing 2026-02-25. The audited primary-source spine — not financial advice.
Revenue — annual (GAAP)
Margins & balance sheet — FY’25
Bull & bear
The category leader of a real, government-and-enterprise-funded quantum-computing market — most revenue, best balance sheet, world-record fidelity, and a vertical-integration land-grab that no listed rival can match. If quantum reaches commercial utility this decade, IonQ is the default US trapped-ion winner.
- Revenue is inflecting hard off a real base: $130M FY25 (+202%) → $260–270M FY26 guide, with $470M RPO giving multi-year visibility — not a pure science project
- Best-capitalized name in the space (~$3.1B cash, ~debt-free) funds the roadmap through the hard years and lets IonQ buy capability (Oxford Ionics, Lightsynq, SkyWater) while rivals scrounge for cash
- Technical credibility is independently validated — AQ 64 at 99.99% two-qubit fidelity and DARPA QBI Stage B selection put IonQ among the few with a credible utility-scale path
- Becoming the only vertically integrated, full-stack US quantum platform (chip → foundry → system → cloud) — a trusted-domestic-supply position defense and government buyers will pay a premium for
- Distribution is solved: available on AWS, Azure, and Google clouds with marquee customers (AstraZeneca, NVIDIA, Lockheed, General Dynamics) already on the systems
A pre-profit science bet trading at ~109x sales whose headline 'profits' are accounting illusions, whose growth is off a tiny government-contract base, and which burns $300M+ a year toward a payoff that is years away and not guaranteed to arrive via trapped ions at all. The price embeds a winner that may not win.
- Valuation is untethered from fundamentals — ~$18.9B market cap on ~$130M revenue (P/S ~109x) prices near-certain dominance of a market that does not commercially exist yet
- The reported GAAP net income is a non-cash warrant-revaluation gain, not earnings; on the real metric (adjusted EPS) IonQ lost $0.34 in Q1 FY26 and MISSED — and guides to a -$310M to -$330M adj. EBITDA loss for FY26
- Burn + serial M&A is funded by issuing stock; the equity-offering / dilution overhang is permanent until profitability, which is not on the visible horizon
- Competition is intensifying and better-funded: Quantinuum (Honeywell, just IPO'd at ~$15.7B) is a direct higher-fidelity trapped-ion rival, and IBM/Google/Microsoft out-resource IonQ across modalities
- Modality risk: if superconducting or neutral-atom reaches fault tolerance first, the trapped-ion roadmap (and the premium) could be stranded; milestones are self-reported and dates have a history of moving across the sector
What it is worth
Reverse-DCF / P-S comp sanity check vs listed quantum pure-plays (QNT, RGTI, QBTS, QUBT). At ~$18.9B on ~$130M FY25 revenue, IONQ trades at P/S ~109x (vs RGTI ~836x, QBTS ~791x on May-2026 marks) — richly valued but the cheapest of the speculative cohort on sales. The price implies the market is underwriting IonQ as the eventual category winner of a commercially-unproven, multi-hundred-billion-dollar TAM. To justify ~$19B at a ~10x mature SaaS-like multiple, IonQ must reach ~$1.9B revenue at healthy margins — i.e. ~15x current revenue and a swing from -$300M EBITDA to durable profitability, plausibly a late-2020s-to-2030 event if (and only if) quantum utility arrives and IonQ wins the modality race.
$6–10B
a milestone slip, fidelity-claim challenge, or risk-off quantum de-rating compresses the multiple toward the 52-wk low (~$26) or below; persistent dilution and Quantinuum competition erode the leader premium.
~$15–20B
revenue compounds toward the $260–270M FY26 guide and beyond, but burn and dilution persist and the modality race stays unsettled; the stock trades sideways-to-volatile around the high-$40s–$50s on sentiment.
$28–40B+
sustained ~100% revenue growth holds, fault-tolerant milestones land on schedule, SkyWater integration delivers trusted-supply government wins, and IonQ is crowned the US trapped-ion winner; the stock re-rates toward $80+.
This is a venture-style, milestone-driven name where fundamentals do not anchor the price — government contracts, fidelity records, and capital raises move it more than earnings. Not financial advice; sizing should reflect binary, long-dated, high-volatility payoff (52-wk range $25.89–$84.64).
SWOT
Strengths
- Largest pure-play quantum revenue ($130M FY25) and the strongest balance sheet (~$3.1B cash, ~debt-free) in the listed group — funded for a multi-year roadmap without near-term forced dilution
- Genuine technical milestones — AQ 64 (64 algorithmic qubits) at world-record 99.99% two-qubit gate fidelity; DARPA QBI Stage B selection validates a credible utility-scale path
- Distribution moat via all three hyperscaler clouds (AWS Braket, Azure Quantum, Google Cloud) plus blue-chip customers (AstraZeneca, NVIDIA, Lockheed Martin, General Dynamics)
- Vertical integration in motion — Oxford Ionics (electronic qubit control) closed; SkyWater (US foundry) pending — toward a uniquely full-stack, supply-secure position
Weaknesses
- Structurally unprofitable with accelerating burn — FY26 adj. EBITDA loss guided -$310M to -$330M; cash runway, while large, is finite against this run-rate
- Headline GAAP 'net income' is non-cash warrant accounting, not earnings — flatters reported results and can mislead; adjusted EPS still deeply negative and missed Q1 FY26
- Revenue base is small and contract-/government-heavy (lumpy, milestone-driven), inflating optics of triple-digit growth off a low base
- Serial-acquirer + equity-funded model dilutes shareholders — integration risk across Oxford Ionics, Lightsynq, and SkyWater simultaneously
Opportunities
- US government quantum push (~$2B committed across the sector in May 2026) and defense programs (SDA, MDA, DARPA) as durable, sticky revenue
- Quantum networking / quantum internet via Lightsynq + photonic interconnect (imec, NKT Photonics) as a second product axis
- Enterprise inflection if demonstrated 20x speedups convert into production workloads (pharma, materials, logistics, finance)
- Owning a US foundry (SkyWater) positions IonQ for 'trusted domestic supply' contracts amid quantum-supply-chain nationalism
Threats
- Quantinuum (Honeywell-backed, IPO'd Jun 2026 ~$15.7B) is a deeper-pocketed, higher-fidelity trapped-ion rival; Google/IBM/Microsoft pursue competing modalities at far greater scale
- Valuation is sentiment-driven (P/S ~109x) — any milestone slip, fidelity-claim challenge, or risk-off rotation can halve the stock (52-wk low $25.89 vs ~$49 now)
- A faster path to fault tolerance from a competing modality (superconducting, neutral-atom, photonic) could strand the trapped-ion architecture
- Persistent equity issuance to fund burn is a standing dilution overhang
Moats, dependencies & bottlenecks
Moats
Funds the roadmap and the M&A land-grab while rivals raise; but it depletes at $300M+/yr and is a war chest, not a structural moat.
Fidelity / technical leadership (AQ 64 at 99.99% 2-qubit fidelity, DARPA QBI Stage B) Real and externally validated, but self-reported milestones and a fast-moving field make any single-metric lead contestable (Quantinuum).
Vertical full-stack integration (chip → SkyWater foundry → system → cloud) if executed Potentially the most durable edge — trusted domestic supply for government — but unproven and integration-risk-laden until SkyWater closes and delivers.
Hyperscaler distribution (AWS + Azure + Google) + blue-chip install base Lowers adoption friction and creates switching inertia; same channels also list competitors, so it's a shared, not exclusive, moat.
Sticky, multi-year, and a credibility signal; the most defensible recurring-revenue source.
Dependencies
Sustained $300M+/yr burn means profitability is not visible; the model depends on raising equity, which dilutes — the standing overhang.
Most customer access flows through partners who also host competing QPUs and run their own quantum programs.
Trapped-ion systems depend on precision optics/lasers; SkyWater addresses trap-chip fab but not the full optical supply chain.
Shareholders approved (May 2026) but close is pending customary/regulatory conditions (Q2/Q3 2026); a break would dent the full-stack thesis.
A meaningful share of revenue is government/defense; appropriations and program timelines are political and lumpy.
Oxford Ionics/Lightsynq founders' retention is part of the acquired value; the talent pool is tiny and contested.
Advantages
- Largest revenue and largest cash balance of any listed quantum pure-play
- World-record two-qubit gate fidelity (99.99%) and DARPA-validated roadmap credibility
- Only listed player pursuing true full-stack vertical integration (foundry to cloud)
- Distribution on all three major clouds plus a blue-chip enterprise + defense customer roster
- First-mover brand recognition as the default 'quantum stock' for institutional and retail capital
Weaknesses
- Deeply unprofitable with widening losses and a permanent dilution overhang
- Headline GAAP profits are non-cash warrant accounting, masking the real adjusted losses
- Revenue base is small, lumpy, and government-contract-heavy — triple-digit growth flatters a low base
- Valuation (~109x sales) leaves no margin for error on milestones or sentiment
- Modality risk: a competing approach reaching fault tolerance first could strand the trapped-ion bet
Bottlenecks
- Path to profitability — burn ($310–330M FY26 adj. EBITDA loss) far exceeds revenue; no credible near-term breakeven
- Scaling qubit count while holding 99.99% fidelity — the core physics gate to commercial utility
- Converting pilots/demonstrations (20x speedups) into recurring production revenue at scale
- Simultaneous integration of three acquisitions (Oxford Ionics, Lightsynq, SkyWater) without execution slips
- Photonics miniaturization (bulk optics → integrated) needed to move from benchtop to data-center-scale systems
Top signals & trends
Top signals
Demand signal is the strongest part of the story; RPO de-risks the top line.
Profitability is moving the wrong way as the company scales spend; the metric that matters disappointed.
Optically positive but economically meaningless — a tell for retail mis-pricing, not value creation.
Third-party validation of technical credibility and a utility-scale path.
Strategically powerful (full-stack, domestic supply) but adds a capital-intensive fab and integration risk; execution-dependent.
Validates the category but pressures IonQ's 'only pure-play leader' premium and invites direct fidelity/roadmap comparison.
Removes near-term funding risk and funds the M&A roadmap; the single best defensive attribute.
Sentiment-driven, high-beta; downside is structural on any risk-off rotation or milestone slip.
Trends
Tailwind for sticky defense/government revenue; IonQ is a primary beneficiary (DARPA, SDA, MDA).
Directly motivates the SkyWater US-foundry play; advantages US-based full-stack vendors.
IonQ leads on fidelity but rivals lead on raw qubit count/scale; the winning modality is unsettled.
Lifts sector sentiment and funding access, but raises the comp set and the bar for differentiation.
20x speedup demonstrations with AstraZeneca/NVIDIA could convert pilots to production — the key fundamental swing factor.
Ecosystem & competitor graph
Suppliers feed the company; customers pull from it. Line thickness shows the strength of each tie (supply-chain dependency, customer earnings contribution). Hover to isolate a tie.
US technology foundry IonQ is acquiring ($35/sh, pending Q2/Q3 2026) to in-source ion-trap chip fabrication — supplier becoming a wholly-owned subsidiary.
Belgian nanophotonics R&D institute; partner to miniaturize trapped-ion optics from bulk to integrated photonics.
Photonics/laser-source partner for advancing trapped-ion light delivery; NKT Photonics is owned by Hamamatsu Photonics.
Acquired Sep 2025 ($1.075B) for electronic qubit control (chip-based ion control) — capability now in-house.
Acquired 2025 for quantum-memory and photonic-interconnect technology toward networked/scaled systems.
Pharma R&D customer; cited in ~20x performance demonstrations on Tempo/Forte Enterprise.
Partner/customer on hybrid quantum-classical (CUDA-Q) workloads and performance demonstrations.
Defense customer/partner.
Defense customer/partner.
DARPA QBI, SDA HALO ($39M tactical-space comms), MDA SHIELD IDIQ — anchor government revenue.
Trading-house enterprise customer (Toyota group).
Simulation-software partner/customer.
Semiconductor enterprise partner/customer.
Honeywell-backed direct trapped-ion rival; IPO'd Jun 2026 at ~$15.7B. Often cited as higher-fidelity and deeper-resourced — the most direct same-modality threat.
Superconducting, modular-chip approach optimized for scalability; tiny revenue (~$7M FY25) but a public pure-play comp and momentum name.
Quantum annealing (optimization-focused), not gate-based; FY25 revenue ~$24.6M at ~83% gross margin — different problem class but competes for the same investor capital.
Superconducting at far greater scale and resources; landed ~$1B of the US quantum-foundry commitment; the gorilla on roadmap and enterprise reach.
Superconducting (Willow); leading error-correction research and effectively unlimited capital — a modality-displacement risk.
Topological qubit research (Majorana) plus Azure Quantum as the cloud aggregator — both a partner channel and a long-dated competitor.
Photonic approach; tiny revenue, extreme P/S — a sentiment-correlated pure-play comp rather than a near-term technical threat.
Neutral-atom approach; received ~$100M in the May 2026 US government quantum package — an emerging modality competitor for government dollars.